<DOC>
	<DOCNO>NCT02315027</DOCNO>
	<brief_summary>The purpose study determine whether mesenchymal stem cell ( MSCs ) safely deliver cerebrospinal fluid ( CSF ) patient multiple system atrophy ( MSA ) . Funding Source - FDA OOPD .</brief_summary>
	<brief_title>Mesenchymal Stem Cell Therapy Multiple System Atrophy</brief_title>
	<detailed_description>The primary aim evaluate safety tolerability intrathecal injection autologous MSCs dose escalation study patient MSA . Safety secondary goal include monitor change peripheral blood component CSF , monitor change nervous system structure use MRI . Efficacy secondary goal include evaluate potential efficacy provide number study instrument detect change course disease term autonomic neurologic symptom deficit .</detailed_description>
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Multiple System Atrophy</mesh_term>
	<mesh_term>Shy-Drager Syndrome</mesh_term>
	<criteria>Inclusion Criteria 1 . Participants age 3080 year old diagnosis MSA base clinical criterion standardize autonomic testing . This approach allow identification patient MSA high specificity yet sensitive enough allow enrollment patient disease stage intervention natural disease course meaningful impact patient outcome . Patients therefore fulfill Gilman Criteria ( 2000 ) probable MSA parkinsonian subtype ( MSAP ) cerebellar subtype ( MSAC ) finding autonomic function test suggestive MSA ( CASS ≥5 TST % ≥25 % ) . 2 . Participants le 4 year time document MSA diagnosis . 3 . Participants anticipated survival least 3 year opinion investigator . 4 . Participants willing able give inform consent . 5 . `` Normal '' cognition assess MiniMental State Examination ( MMSE ) . We require value &gt; 24 . Exclusion Criteria Any follow condition exclude participant enter study : 1 . Women childbearing potential practice acceptable method birth control . Acceptable method birth control study : surgical sterilization , intrauterine device , partner 's vasectomy , doubleprotection method ( condom diaphragm spermicide ) , hormonal contraceptive drug ( i.e. , oral contraceptive , contraceptive patch , longacting injectable contraceptive ) require second mode contraception . 2 . Participants clinically significant unstable medical surgical condition , opinion investigator , might preclude safe completion study might affect result study . These include condition cause significant central nervous system ( CNS ) autonomic dysfunction , include congestive heart failure , recent ( &lt; 6 month ) myocardial infarct , cardiopulmonary disease , severe , uncontrolled hypertension , thrombocytopenia ( &lt; 50 x 10 ( 9 ) /L ) , severe anemia ( &lt; 8g/dl ) , immunocompromised state , liver kidney disease ( creatinine &gt; 2.3mg/dl ) , uncontrolled diabetes mellitus ( HbA1c &gt; 10g % ) , alcoholism , amyloidosis , uncontrolled hypothyroidism , sympathectomy , unstable peripheral neuropathy , concurrent infection , orthopedic problem compromise mobility activity daily living , cerebrovascular accident , neurotoxin neuroactive drug exposure , parkinsonism due drug ( include neuroleptic , alphamethyldopa , reserpine , metoclopramide ) . 3 . Participants malignant neoplasm . 4 . Participants take investigational product within 60 day prior baseline . 5 . Medications could affect autonomic function . If patient take medication , suspend prior autonomic testing . Therapy midodrine , anticholinergic , alpha beta adrenergic antagonist medication affect autonomic function withdraw 48 hour prior autonomic evaluation . Fludrocortisone dose 0.2 mg per day permit . 6 . Diseases feature Parkinsons Disease ; e.g. , diffuse Lewy body disease , progressive supranuclear palsy , essential tremor , hereditary olivopontocerebellar atrophy , postencephalitic parkinsonism . 7 . Dementia ( DSMIV criterion American Psychiatric Association 1994 ) . The score MiniMental State Examination must &gt; 24 . 8 . History electroconvulsive therapy . 9 . History brain surgery Parkinsons disease . 10 . Patients contraindication MRI scanning , include MRIincompatible pacemaker 11 . Patients active systemic infection local infection , close spinal injection site</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>